Optimus Pharma gets DCGI gesture to lead Phase-3 preliminary of COVID-19 antiviral drug Kumar Jeetendra | May 19, 2021 The orally administered drug is being tested for treating mild and moderate infection Optimus Pharma has obtained the approval of the Drug Controller General of India (DCGI) to conduct Phase III clinical trials of orally administered Molnupiravir capsules on patients with mild and moderate Covid-19 infection. In accordance with the clinical trial protocols approved, a …
Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19 Kumar Jeetendra | June 29, 2021 India. June 29, 2021 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”), Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”), Emcure Pharmaceuticals Limited (hereafter referred to as “Emcure”), Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, …
New drug Molnupiravir can be the solution for our fight against COVID-19 Kumar Jeetendra | December 28, 2021 Mumbai, 28th December 2021: As countries prepare themselves to fight a possible ‘next wave’. The new variant – Omicron has been making headline and a surge in covid 19 cases are evident. According to a study based on population-level evidence, the recently identified Omicron variant of SARS-CoV-2 is associated with a substantial ability to evade …
